Drug Profile
Research programme: dopamine D4 receptor antagonists - Sanofi-Aventis/NPS Allelix
Alternative Names: Dopamine D4 receptor antagonists research programme - Aventis/NPS AllelixLatest Information Update: 24 Jan 2005
Price :
$50
*
At a glance
- Originator NPS Allelix; sanofi-aventis
- Developer sanofi-aventis
- Class
- Mechanism of Action Dopamine D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 24 Jan 2005 Discontinued - Preclinical for Schizophrenia in USA (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 10 Feb 2000 Allelix Biopharmaceuticals has merged with NPS Pharmaceuticals